Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy.
Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.
The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.
2017 年奥地利维也纳举行的第 15 届圣加仑国际乳腺癌会议回顾了早期乳腺癌局部和全身治疗的大量新证据。评估了这些治疗方法的强度、持续时间和副作用,根据肿瘤分期和肿瘤生物学预测的可能获益,寻求适当的治疗升级或降级。专家组倾向于几种可能减少手术发病率的干预措施,包括接受 DCIS 2mm 切缘、接受新辅助治疗的女性切除残留癌(而不是基线癌的范围)、接受新辅助治疗后的前哨淋巴结活检,以及在 HER2 阳性和三阴性、Ⅱ期和Ⅲ期乳腺癌中首选新辅助治疗。专家组赞成在高危患者中升级放疗和区域淋巴结照射,同时鼓励在低危患者中避免放疗。专家组认可了允许许多 ER 阳性乳腺癌患者避免化疗的基因表达谱。对于具有更高风险肿瘤的女性,专家组升级了辅助内分泌治疗的建议,包括绝经前女性的卵巢抑制和绝经后女性的延长治疗。然而,低危患者可以避免这些治疗。最后,专家组建议绝经后妇女使用双膦酸盐预防乳腺癌复发。专家组认识到,这些建议不是针对所有患者的,而是为了解决大多数常见表现的临床需求。辅助治疗的个体化意味着要根据肿瘤特征、患者合并症和偏好来调整,并要考虑治疗成本和可及性的限制,这些可能会影响发达国家和发展中国家的护理。